CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.
Earlier this month, CRISPR Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
Summit Therapeutics has generated plenty of buzz in the biotech industry over the past two years. That's because the ...
Hosted on MSN
Dyadic outlines new commercial focus as first bulk protein sales and Asia expansion accelerate growth trajectory
Hazelton confirmed Dyadic expects momentum to build with additional product opportunities in 2025, accelerating in 2026 as the company scales its portfolio and expands its global market reach. He ...
Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...
CRISPR-Cas9 genome editing enzyme. [Artur Plawgo / iStock / Getty Images Plus] We need a patient-first approach for any variant in any patient, whomever, wherever they are. Each and every patient ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback